Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Sectornieuws - Biotech en Pharma

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Sectornieuws - Biotech en Pharma

690 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 35 »» | Laatste | Omlaag ↓
  1. forum rang 4 harvester 10 maart 2009 15:30
    clevers achtergrond art. - bionieuws 14, 22-09-2006

    nieuws
    KNAW in de biotech start-up

    Door 0
    © bionieuws

    De KNAW heeft samen met Hans Clevers een nieuw biotechbedrijf opgericht: Agamyxis BV. Het bedrijf gaat zich richten op de ontwikkeling van nieuwe behandelingen van darmtumoren op basis van gamma-secretaseremmers. Deze medicijnen zijn oorspronkelijk ontwikkeld voor de behandeling van de ziekte van Alzheimer. Ze bleken echter onoverkomelijke bijwerkingen in de darmen te hebben, die echter wel uitgangspunten boden voor de behandeling van darmtumoren, bleek uit Clevers’ onderzoek. Het nieuwe bedrijf krijgt als directeur Ton Logtenberg, oprichter van Ubisys en Crucell. Clevers, tevens directeur van het Utrechtse Hubrechtlaboratorium, wordt verantwoordelijk voor het wetenschappelijk onderzoek. Agamyxis werkt op dit moment al samen met farmabedrijf Merck.

    [quote=Nul N. Noppes]
    [quote=Het Financieele Dagblad]
    Hans Clevers
    7 maart 2009 | Het Financieele Dagblad
    1
    Door: Engelenburg, H.

    'Ik ben zonder overdrijving een van de succesvolste wetenschappers in Nederland van dit moment'

    (...)

    [Modbreak IEX: Gelieve persberichten van het FD niet volledig te kopiëren.]
  2. flosz 10 maart 2009 15:49
    quote:

    Het Financieele Dagblad schreef:

    Clevers startte intussen met Logtenberg het biotechbedrijf U-Bisys dat later als Crucell naar de beurs ging.
    ...dat later samen met IntroGene als Crucell naar de beurs ging!

    Leiden/Utrecht, The Netherlands, 30 June 2000 --- IntroGene BV and U-BiSys BV today announced the merger of the two companies. The two companies will together be called Crucell, and will have 150 employees. Financial details were not disclosed. IntroGene's President and Chief Executive Officer, Dinko Valerio, Ph.D. will lead Crucell as President and Chief Executive Officer. Ton Logtenberg, Ph.D., Founder and Chief Executive Officer of U-BiSys will serve as Chief Scientific Officer for Crucell.

    Crucell will integrate IntroGene's existing human cell line expression platform, PER.C6(TM), and U-BiSys' phage antibody-display library technology, which enables the creation of fully human monoclonal antibodies, thus forming a powerful platform for the discovery of drug targets, and the development and production of human biopharmaceuticals.
    *************
    Ton Logtenberg
    is de meest succesvolle wetenschapper/ondernemer uit de geschiedenis van de Universiteit Utrecht.

    www.ublad.uu.nl/WebObjects/UOL.woa/3/...
  3. forum rang 10 voda 10 maart 2009 16:19
    PREVIEW: OncoMethylome verlies 2008 EUR12,6 miljoen - ING


    AMSTERDAM (Dow Jones)--OncoMethylome Sciences heeft over 2008 een verlies geleden van EUR12,6 miljoen bij een omzet van EUR2,9 miljoen. Dat is de verwachting van ING-analist Luke Poloniecki. Een jaar eerder schreef het biotechbedrijf een verlies van EUR9,9 miljoen in de boeken, terwijl een omzet werd gerealiseerd van EUR2,6 miljoen. Poloniecki verwacht dat de kaspositie is verbeterd naar EUR28,8 miljoen door de onderhandse plaatsing van aandelen in december 2008. De analist stelt dat OncoMethylome over een gezonde financiele positie beschikt om het bedrijf in 2011 naar winstgevendheid te leiden. Investeerders zullen volgens ING uitkijken naar nieuws over de ontwikkeling en lancering van producten. Het bedrijf opent donderdag de boeken over het afgelopen jaar. Omstreeks 12.40 uur noteert het aandeel 1,4lager op EUR5,03. (BTZ)



    Dow Jones Nieuwsdienst: 31-20-5715200; amsterdam@dowjones.com

  4. forum rang 10 voda 10 maart 2009 16:32
    Wat een enorm aantal. Er valt nog veel te verbeteren in de wereld...

    Bacterie doodt 800.000 kinderen per jaar
    10 maart 2009, 14:34 | ANP
    JOHANNESBURG (ANP) - Bacteriën die longontsteking, hersenvliesontsteking en infecties aan het bloed veroorzaken doden meer dan 800.000 kinderen per jaar. Afrika loopt daarbij het grootste risico op besmettingen, meldden experts in twee medische rapporten die dinsdag in Johannesburg zijn gepresenteerd.

    De pneumococcus-bacterie wordt via menselijk contact verspreid en kan onder meer longontsteking veroorzaken. Ongeveer 1,6 miljoen mensen sterven jaarlijks wereldwijd aan de gevolgen van die aandoening. De helft van de slachtoffers zijn kinderen jonger dan vijf. Longontsteking veroorzaakt meer sterfgevallen onder kinderen dan aids, mazelen en malaria samen.

    Wanneer de bacterie de hersenen binnendringt, zorgt het bij één op de vier kinderen voor ernstige aandoeningen, waaronder verlamming, epilepsie, doofheid en ontwikkelingsachterstand.

    Er bestaan meer dan negentig verschillende soorten pneumococcus-ziekten die meestal met penicilline worden bestreden. Ook voorhoofdsholteontsteking wordt veroorzaakt door de pneumococcus-bacterie.

  5. ved 12 maart 2009 19:15
    Kaiser Daily Health Policy Report


    Capitol Hill Watch | Rep. Waxman Introduces Legislation That Would Create Regulatory Path for Generic Biotech Drugs
    [Mar 12, 2009]
    House Energy and Commerce Committee Chair Henry Waxman (D-Calif.), Health Subcommittee Chair Frank Pallone (D-N.J.) and the subcommittee's ranking member Nathan Deal (R-Ga.) on Wednesday introduced a bill (HR 1427) that would permit FDA to approve generic versions of biotechnology drugs, CQ Today reports (Armstrong, CQ Today, 3/11). Although Waxman has twice before unsuccessfully introduced similar legislation, "this time may be different" because of his stature as chair of the Energy and Commerce Committee, Congress' desire to reduce drug spending and a mention of the need for generic biotech drugs by President Obama in his budget proposal, the Wall Street Journal reports (Mundy, Wall Street Journal, 3/12).

    The bill would grant generic biotech drug manufacturers regulatory approval if they demonstrate that there are "no clinically meaningful differences" between a generic and the existing biotech drug (CQ Today, 3/11). The bill grants FDA the authority to decide what kind of studies are necessary to determine the equivalence between the drugs and whether generics, also known as biosimilars, are interchangeable with the original (AP/Los Angeles Times, 3/12).

    The bill would grant the makers of original biotech drugs a five-year exclusivity period, plus an optional three-year extension for modified versions and an additional six months if the manufacturer conducts a pediatric study on the drug (Edney, CongressDaily, 3/11). The exclusivity period would be retroactive, meaning that if the bill becomes law, "scores of biotech drugs that were approved years ago would suddenly have generic rivals," CQ Today reports. The bill also would grant the first maker of a generic biotech drug six months of market exclusivity for its version of the treatment (CQ Today, 3/11).

    A companion Senate bill is expected to be introduced shortly by Sens. Charles Schumer (D-N.Y.) and Sherrod Brown (D-Ohio). Sens. Susan Collins (R-Maine) and David Vitter (R-La.) are expected to be key co-sponsors. Waxman said he is not sure when the Energy and Commerce Committee will mark up the bill (CongressDaily, 3/11).

    Reps. Anna Eshoo (D-Calif.) and Joe Barton (R-Texas) in 2007 introduced legislation that "was more favorable to brand-name biotech companies" because it granted them 12 years of exclusivity instead of five, the Journal reports (Wall Street Journal, 3/12). Eshoo and Barton on Thursday are likely to reintroduce their bill, according to CongressDaily (CongressDaily, 3/11).

    Comments
    Pallone said, "By creating a pathway for generic biologics, we hope to increase access to these lifesaving drugs, lower prices and spur innovation." The biotech industry has said it will lobby against the legislation. Industry officials have said that the short exclusivity periods will undermine innovation because companies will lack the financial incentives to conduct new research (CQ Today, 3/11). Former Rep. James Greenwood (R-Pa.), the president of Biotechnology Industry Organization, said in a statement, "This bill seeks to cut prices but instead cuts corners," adding that the legislation "jeopardizes the continued development of breakthrough therapies and potential cures for debilitating disease such as multiple sclerosis, HIV/AIDS and Alzheimer's" disease (Wall Street Journal, 3/12).

    Biotech companies also said that generic versions are not exact copies of the brand-name versions because of the complex nature of the treatments (CQ Today, 3/11). Biotech companies suggested that all biosimilars undergo comprehensive clinical trials in order to demonstrate their safety and effectiveness (Wall Street Journal, 3/12).

    www.kaisernetwork.org/daily_reports/r...
  6. [verwijderd] 14 maart 2009 13:48
    Big Mergers Could Mean Sweet Gains for Biotech
    March 13, 2009

    Marc Lichtenfeld

    Talk about a winter of discontent…

    Over the past seven weeks, we’ve seen quite possibly one of the best examples of stock market fear in history.

    Actually, it’s not fear. It’s pure irrationality, as top-quality stocks have been spanked down to bargain-basement levels, despite no discernible change in their businesses.

    But business is still booming in the biotech sector…

    Over that time, we’ve seen three huge buyouts occur in the Big Pharma/biotech area…

    It started in January, with the news that Pfizer (NYSE: PFE) would shell out $68 billion to buy Wyeth (NYSE: WYE).

    And things really got rolling this week, with the news that Merck (NYSE: MRK) will acquire Schering-Plough (NYSE: SGP) for $48 billion and that Roche (RHHBY.PK) and Genentech (NYSE: DNA) have finally concluded protracted negotiations that will see Roche buy the biotech superpower for $47 billion.

    Total value of done deals: $163 billion. And in a market where access to capital has supposedly dried up.

    The question is: Could these Big Pharma mergers signal a shift in sentiment and a bottom for the broader stock market?

    If you’re looking for a simple, one-word answer… no.

    But if you don’t take your investment advice from such in-depth, hard-hitting features as the “Lightning Round,” I invite you to keep reading…

    The Credit Is There… But Only For The Right Deal
    There’s no doubt that it’s tough to get credit these days. But as the merger deals above show, capital is clearly available for the right deals.

    For example, in order to finance its deal with Genentech, Roche issued nearly $33 billion in notes. In addition, Pfizer received over $22 billion in loan commitments from various banks to complete its transaction. And similarly, J.P. Morgan (NYSE: JPM) slapped down $8.5 billion so Merck could fund its deal with Schering-Plough.

    Again, this has occurred during one of the most fear and panic-ridden periods in stock market history. And it’s come despite frequent comparisons of the Depression Era. Listen to the media too much and you’d expect to see the world in a grainy, brown hue every time you look out the window.

    Don’t get me wrong here: I’m keenly aware that the economy is in bad shape. No one has ever accused me of being a Polyanna. But my point is that it’s not necessarily all doom-and-gloom (as some would like you to believe).

    These healthcare/biotech mergers indicate the beginning of a thaw in credit markets and hopefully the start of a healing process for the markets. Notice that I’m not calling it a “bottoming process” because as I said last week, I do believe we’ll see new stock market lows.

    But as more deals get done, investor and lender confidence will slowly return to the market. And I do think more acquisitions are imminent - particularly within the biotech sector…

    The Biotech Sector - A Wave of Consolidation
    The biotech sector is likely in store for a wave of consolidation. While the above-mentioned Big Pharma companies have boosted their pipelines and created massive biopharma companies with their acquisitions, there are still many pharmaceutical companies that desperately need to fill their pipelines.

    And that bodes well for biotech - particularly when you consider that the largest biotech company after Genentech is Amgen (Nasdaq: AMGN), which boasts a market cap of $48 billion.

    After that, Gilead Sciences (Nasdaq: GILD), which just announced a $1.4 billion takeover of CV Therapeutics (Nasdaq: CVTX), is next at $40 billion. Then the market thins considerably, with only three companies that have market caps over $10 billion and 11 companies with market caps of $1 billion or more.

    For example, Merck could buy Biogen (Nasdaq: BIIB) and Genzyme (Nasdaq: GENZ) for less than it cost the firm to buy Schering-Plough.

    The point is: Even though the biotech sector has outperformed the S&P 500 during the bear market, many biotech stocks have become cheap.

    In fact, pharmaceutical companies wouldn’t even need to raise capital to buy a BioMarin (Nasdaq: BMRN), or Xcelerated Profits Report portfolio member Medivation (Nasdaq: MDVN) and many others like them.

    Our 2 Favorite Emotional Friends: Fear And Greed
    When managements are scared they hunker down and hang on to capital. But when opportunistic executives add to their businesses - even during downturns - that kind of optimism and activity is healthy. They’re essentially expressing their confidence that conditions will improve.

    Remember… emotions control the stock market as much as fundamentals. And as we’ve mentioned in previous columns, fear and greed are the two main players. So when investors see this kind of activity, they start to think about their own opportunities, rather than cowering in the corner in the fetal position like so many have for the past few months.

    Big Pharma Falls For Attractive Biotech

    As we’ve seen recently, Big Pharma has already fallen for some of the most attractive biotech names. And as some more choice companies begin to get snapped up, you might see a rush into the sector by other Big Pharma firms to grab the existing quality companies before someone else does.

    Mix in this momentum with some speculation and that could kick prices higher, causing Big Pharma executives to pull the trigger before valuations get too expensive.

    The economy is still bleeding, but these recent acquisitions indicate that the patient is no longer spurting blood all over the emergency room floor. Eventually, it will stabilize and walk on its own again.

    When it does, the strongest drug companies will be the ones that took advantage of this unique opportunity to fill their pipelines with products from inexpensive biotech companies.

    seekingalpha.com/article/125895-big-m...
  7. [verwijderd] 14 maart 2009 14:08
    Biopharma, Especially Merck, Having a Good Week
    March 13, 2009

    Mike Huckman

    Shares of Dow component Merck (MRK) are getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.

    Dr. Anderson says the stock price was too low -- tied with Pfizer (PFE) for the lowest forward price-to-earnings multiple -- for a company that he calls a "best-in-class grower." In a research note to clients he writes, "MRK/SGP offers the highest growth of the 10 names we cover in the US and Europe." In an accompanying voiceblast Dr. Anderson said, "Lowest valuation with the highest growth, with a nice dividend yield and a near-term pipeline, what's not to like?" Regarding the near-term pipeline, Dr. Anderson singled out a heart attack prevention drug owned by Schering-Plough (SGP) that "could potentially be a multi-billion dollar product."

    He acknowledges that a potential dispute over SGP's pre-existing relationship with Johnson & Johnson could throw a wrench into the whole thing, especially if JNJ (JNJ) gets into a bidding war with MRK for SGP. Many analysts have said that could happen. But even if MRK were to lose that fight, Dr. Anderson says Merck would likely walk away with the keys to the whole cholesterol drug joint venture with SGP that includes Vytorin and Zetia. He estimates that would immediately add 15-20 percent to MRK's earnings.

    Yes, the overall market has had a good week. But the biopharma ticker, especially over the last couple of days, seems to be picking up steam. I think it could be a combination of factors: speculation about the next takeout target, a reaction to what many thought was a stock-market overreaction to President Obama's proposed healthcare reform plan, a relief rally because it looks like the next FDA Commissioner won't be Dr. Steve Nissen, and maybe some of it's all the money coming out of Genentech (DNA) finding new homes.

    seekingalpha.com/article/125918-bioph...
  8. eddy59 14 maart 2009 20:31


    Text Size Mar.13
    9:37 PM ET 17 hours ago
    Promise for Prostate Cancer Treatment?
    Posted By: Tom Brennan
    Topics:Stock Picks | Stock Market
    Sectors:Biotechnology
    Companies:Cougar Biotechnology, Inc. | Bristol-Myers Squibb Co | Genzyme Corp | Cephalon, Inc. | Biogen Idec Inc | Celgene Corp
    Biotech is the best sector in which to speculate right now, Cramer said Friday. The $193 billion in takeovers just in the past month indicates there’s a good chance to find another winning stock here.

    Cramer likes Cougar Biotechnology [CGRB 27.77 0.73 (+2.7%) ] for its upcoming prostate cancer treatment. Abiraterone is in Phase III trials, and the Food & Drug Administration has given the drug “special protocol assessment” because it treats an unmet need. If the FDA gives Abiraterone the thumbs-up, then Cougar might enjoy patent protection until as late as 2017.

    Abiraterone works by preventing prostate cancer cells from getting the hormones that stimulate their growth, and the study data so far looks promising. One Phase II trial showed that 71% of patients who took the drug saw a more than 50% reduction in prostate-specific antigens, or PSAs. Doctors look for these PSAs when they test for the disease. So the fewer they find, the better the drug is doing its job. Another Phase II trial showed that 48% of patients saw that 50% PSA reduction. This is all good news, Cramer said, given how hard prostate cancer can be to treat.

    The Phase III trials have been split in two: one for post-chemotherapy patients, which started in April 2008, and one for pre-chemo that started early this year. Interim data for the post-chemo trial should come in the second half of 2009, with the pre-chemo info coming in the first half of 2010. As we said, the FDA has a watchful eye on these trials, and the successes in Phase II should carryover this time around. Good news would send Cougar shares higher.

    Admittedly, previous prostate treatments have failed for other biotech firms, but Cramer seemed positive. The company is sitting on enough cash to last another two years without an additional infusion, and two other drugs in the pipeline – one for multiple myeloma, a kind of blood cancer, and another prostate cancer treatment – are in Phase I development. If Abiraterone passes with FDA approval, companies like Celgene [CELG 48.20 1.04 (+2.21%) ], Biogen Idec [BIIB 48.50 -0.38 (-0.78%) ], Cephalon [CEPH 66.32 1.92 (+2.98%) ], Genzyme [GENZ 56.14 0.51 (+0.92%) ] and Bristol-Myers Squibb [BMY 20.95 0.17 (+0.82%) ] could come knocking.

    Keep in mind, though, that no matter how bullish the case, this is still a speculation stock. Cougar’s market cap is less than $600 million. So use limit orders and build a position slowly, buying small quantities each time. And be patient – investors shouldn’t pay up for this stock.

  9. [verwijderd] 18 maart 2009 14:13
    Takeda Forced to Surrender DPP-IV Drug Market to Merck
    March 17, 2009

    Derek Lowe

    DPP-IV is short for “dipeptidylpeptidase IV”, understandably, and we need a good abbreviation for it. It’s an important enzyme target for diabetes therapy, since under normal conditions it breaks down glucagon-like-peptide 1. Longer-circulating GLP-1 would actually do a lot of diabetics good, and people have actually made such proteins as separate drugs, so inhibiting an enzyme that clears it out looks like a good bet. Of such reasoning are drug targets made.

    A lot of companies have bought into this reasoning, for sure. For quite a while, Novartis (NVS) looked like the leader in the area, with the most advanced clinical candidate and a lot of publications in the literature from their development work. But Merck (MRK) turned out to be running a big effort of their own, and actually got to market first with Januvia (sitagliptin).

    Novartis’s drug (Galvus, vildagliptin) looks as if it will never make it at all here in the US. They had to slow down development due to some troubling side effects, giving Merck the edge. There are several DPP subtypes, and you need to be pretty selective, as it turns out – at least some of the problems stem from that consideration. This wasn’t fully appreciated in the first wave of development in this area – the pioneers had to figure it out the hard and expensive way. But a number of companies have come up behind, trying to get a piece of the market, and they now have a clearer idea of what they need to accomplish.

    Or do they? Takeda (TKPHF.PK) recently heard from the FDA that their DPP-IV inhibitor alogliptin has been turned down for now. What’s more, the agency wants more cardiovascular safety data from them and from anyone else who comes in with a drug in that category. Cardiovascular problems have always been the weak point for Type II diabetes drugs, to be sure. The patient population tends to be older and overweight, often with elevated blood pressure, so you really don’t have much room to work in when it comes to side effects. That’s led to a lot of attempts to come up with therapies that address the CV side of things at the same time as glucose levels (such as the ill-fated disaster of the PPAR alpha-gamma compounds, all of when went most expensively down in flames). DPP-IV inhibitors wouldn’t be expected to have any direct CV benefits, but they do have to avoid making things any worse.

    So Merck looks to have the market to itself for a while longer, but as the only DPP-IV drug on the market, they’re going to be under a good deal of scrutiny. The company has already had its share of post-launch cardiovascular nightmares; you’d think that they’re going to work hard to avoid any more. And now all we have to do is assure ourselves that the actions of the DPP-IV inhibitors are all through making GLP-1 last longer. Because even if you're selective for that one enzyme, it has a lot of other substrates. So the story may well swing back to the biochemical mechanism again before we're through.

    seekingalpha.com/article/126395-taked...

  10. [verwijderd] 18 maart 2009 14:17
    Merck and Pfizer Need to Follow Abbott's Lead
    March 17, 2009

    Mark Cifra

    Let me disclose this right upfront: I'm not a fan of big mergers. I don't think they work for shareholders and I can't find examples to make me think differently. Pfizer (PFE), for instance, has already merged with Warner Lambert and Pharmacia, yet the stock of Pfizer has been trading at or near multi year lows. What makes Pfizer management think another large merger, in this case Wyeth (WYE), will work? I personally don't see their logic.

    Merck (MRK), on the other hand, has only managed a few small buyouts over the last few years. With Merck stock at or near multi year lows, maybe a Schering Plough (SGP) buyout will work for shareholders, but I am taking a wait and see attitude on this deal.

    What I think Pfizer and Merck need to do is what Abbott Labs (ABT) did in December 2000: find a company with a pipeline that has a lot of potential and buy it, in this case, Knoll Pharmaceuticals. With the buyout of Knoll came the worldwide rights to Humira, a drug that would not be approved in the US for several more years, but had great potential at the time. Abbott paid 6.9 billion dollars to buy Knoll. Humira sales in 2008 were 4.5 billion. 6.9 billion paid for a drug that will probably top 10 billion in sales in one single year before it loses patent protection, of course by then.

    Abbott plans on having another drug take Humira's place, ABT-874, which Abbott also got in the Knoll buyout. Not a bad deal for Abbott shareholders, who have definitely performed much better than Pfizer and Merck shareholders over the last 5 years.

    seekingalpha.com/article/126379-merck...

  11. ved 18 maart 2009 16:37
    Biosimilar bill offers 12 years of market exclusivity
    March 18, 2009 — 10:35am ET | By John Carroll

    Biotech lobbyists loudly cheered a newly-introduced bill that offers 12 years of market exclusivity to branded biologics before they have to confront a generic competitor. Reps. Anna G. Eshoo (D-CA), Joe Barton (R-TX) and Jay Inslee (D-WA) introduced the bill, which quickly earned rave reviews from BIO.

    The bill "provides patients with the right balance between innovation and competition," said BIO President Jim Greenwood.

    Greenwood and the rest of the biotech industry, though, face tough legislative competition from a bill offered by Henry Waxman that provides only five years of exclusivity for biologics. After years of wrangling over issues like the safety of biosimilars and the kind of discounts that they could offer the marketplace, lawmakers are now down to only one: How much time should a biologic be given before a biosimilar is allowed to compete with it?

    For biotech companies, the difference between five years and 12 years of exclusivity could amount to billions of dollars. Mega-blockbusters earn more than $2 billion a year. But there's a lot of support in Congress to pass those savings on to consumers as soon as possible. And the debate appears headed for a final resolution sometime this year.

    - read the report from Dow Jones
    - here's BIO's response

    Related Articles:
    Lawmakers propose biogeneric bill
    Obama to back biogenerics
    Small biotech campaigns for biogenerics law
    Biotech's next big opportunity: Follow-ons?

    www.fiercebiotech.com/story/new-biosi...
  12. forum rang 10 voda 19 maart 2009 12:44
    'Proteïne veroorzaakt aanval bij alzheimerpatient'
    19 maart 2009, 12:02 | ANP
    ABERDEEN (ANP) - Onderzoekers in Schotland hebben een verband gevonden tussen de ziekte Alzheimer en epilepsie. Dit heeft BBC News donderdag gemeld.

    Proeven met muizen wezen uit dat zetmeelachtige proteïnes, die klonters vormen in de hersenen, zenuwcellen gevoeliger en vatbaarder maken voor epileptische aanvallen.

    Als dit ook het geval is bij mensen, hetgeen te verwachten is, dan hebben alzheimerpatiënten andere medicijnen nodig dan die ze nu krijgen, meent professor Tibor Harkany.

    Acetylcholine

    De medicijnen die op dit moment worden gebruikt, zorgen voor een vermindering van de afbraak van de neurotransmitter acetylcholine. Deze stof in de hersencellen speelt een belangrijke rol bij de werking van ons geheugen.

    Een nadelige bijwerking is echter dat de kans op epilepsieaanvallen groter wordt. Doordat medicijnen tegen epilepsie de symptomen van alzheimer verergeren, staan artsen voor een medisch dilemma.

    Een derde van de alzheimerpatiënten heeft last van epileptische aanvallen. Sommigen hebben ongeveer tachtig keer vaker last van een aanval dan mensen zonder alzheimer.

  13. forum rang 10 voda 19 maart 2009 13:15
    Digitaal opsporen borstkanker gaat sneller
    19 maart 2009, 13:07 | ANP
    BILTHOVEN (ANP) - ,,Dit is goed nieuws voor alle vrouwen'', zegt Marc Sprenger directeur-generaal van het Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Bij het instituut werd donderdag het startsein gegeven voor een nieuw landelijk systeem voor het maken van digitale borstfoto's. Door de digitale fotografie kan borstkanker eerder worden opgespoord, aldus Sprenger.

    Jaarlijks krijgen een miljoen vrouwen tussen 50 en 75 jaar een uitnodiging om mee te doen aan het bevolkingsonderzoek borstkanker. Het onderzoek is bedoeld om vroegtijdig te ontdekken of iemand borstkanker heeft. Dankzij dit bevolkingsonderzoek overlijden jaarlijks 750 vrouwen minder aan borstkanker.

    Vanaf de zomer moet de helft van alle apparatuur waarmee de borstfoto's worden gemaakt, digitaal zijn.

  14. forum rang 10 voda 19 maart 2009 13:55
    DSM gaat samenwerken met Chinese farmaceut
    19 maart 2009, 13:46 | ANP
    HEERLEN (AFN) - Chemieconcern DSM gaat met het Chinese farmaceutische bedrijf NCPC samenwerken op het gebied van voedingsproducten en penicilline. De bedrijven hebben daarvoor de contracten getekend, zo meldde DSM donderdag.

    DSM investeert bijna 110 miljoen dollar. Het gaat om drie samenwerkingsverbanden. Deel van de afspraken is dat DSM een strategische investering doet in NCPC door een minderheidsbelang te kopen dat een omvang van 10 procent nadert.

    Er komt een samenwerkingsverband op het gebied van voedingsmiddelen en twee op het gebied van penicilline. In die laatste twee krijgt DSM een belang van 51 procent, in de eerste een minderheidsbelang van 30 procent. Met de uitvoering van de overeenkomsten wordt in de tweede helft van dit jaar begonnen.

    De contracten zijn een vervolg op aankondigingen die eind 2004 zijn gemaakt en een uitwerking van een overeenkomst van eind 2005.

  15. Alpen 19 maart 2009 17:53
    Dus Pfizer heeft, naast afhandeling van de Wyeth deal, nog wat tijd & geld (?) over om te shoppen.
    Het betreft dan wel de generieke hoek, maar misschien toch eerder "actief", of iets wat daarop lijkt, dan de concurrent zou verwachten.

    Pfizer eyes takeovers to boost generics unit -paper

    FRANKFURT, March 19 (Reuters) - U.S. drugs giant Pfizer Inc (PFE.N) is eyeing takeovers as a way to boost its generics business, German business daily Handeslblatt quoted a top company executive as saying.

    "We want to expand our product portfolio in this area," it quoted generics division head David Simmons as saying in an interview printed on Thursday.

    Steps to this goal could include "developing new products ourselves, buying licences or acquiring companies", it said.

    Generics are copies of drugs that have lost patent protection. (Reporting by Michael Shields, editing by Will Waterman)

    www.reuters.com/article/rbssHealthcar...

  16. [verwijderd] 22 maart 2009 21:26
    FDA and Clinical Trial Calendars: Favorable Vote for Sanofi's Multaq
    March 22, 2009

    Mike Havrilla

    Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars.

    The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description.

    The Clinical Trial Calendar includes 137 entries through 3/20/09 and encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.

    1.) OSI Pharma (OSIP) and Roche (RHHBY.PK): Supplemental new drug application (sNDA) to expand the labeled use of Tarceva (erlotinib) as a first-line maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy. The PDUFA decision date would be 1/19/09 for a standard, 10-month review.

    Both the U.S. and EU submissions are based on a pivotal Phase 3 clinical trial known as SATURN.. In November 2008, OSI, Genentech and Roche announced that SATURN met its primary endpoint and showed that Tarceva significantly extended the time patients with advanced NSCLC lived without their cancer getting worse (progression-free survival or PFS) when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo.

    The SATURN data will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology being held May 29-June 2, 2009 in Orlando, Fla.. Overall survival data, a secondary endpoint of the study, are expected in 2H09 and will be part of the FDA review process. Roche also filed in parallel for EU approval for this indication with the EMEA.

    2.) Johnson & Johnson (JNJ) and Bayer's (BAYRY.PK) anticoagulant drug Xarelto (rivaroxaban) was backed by a U.S. advisory panel on Thursday by a 15-2 vote despite concerns over possible side effects (bleeding and liver damage). The companies are seeking marketing approval for the once-a-day pill to prevent dangerous blood clots for up to 14 days in patients following knee replacement surgery and up to 35 days for hip replacements. The drug is already used in Europe and Canada with a PDUFA decision date of 5/28/09 for the final FDA decision.

    3.) Sanofi-Aventis (SNY): An FDA Advisory Panel of cardiology experts voted 10-3 in favor of Multaq (dronedarone) as a treatment for atrial fibrillation (a-fib), which is the most common type of irregular heartbeat that affects the upper chambers of the heart and carries a significant risk of causing a stroke. A final FDA decision is expected by the end of April. Analysts are predicting blockbuster sales of over $1B per year for Multaq and, if approved, it would represent the first new treatment for a-fib in over two decades.

    seekingalpha.com/article/127209-fda-a...

  17. forum rang 10 voda 23 maart 2009 16:46
    Britse gaan synthetisch bloed maken
    23 maart 2009, 7:36 | ANP
    LONDEN (ANP) - Britse wetenschappers willen als eersten in de wereld onbeperkte hoeveelheden menselijk bloed maken voor bloedtransfusies. Dit heeft de krant The Independent maandag gemeld.

    Voor het project, dat gebruik maakt van stamcellen, moeten embryo's worden gebruikt die 'over' zijn bij ivf-behandelingen. Daaruit worden via dna-tests embryo's geselecteerd die genetisch geprogrammeerd zijn om uit te groeien tot een mens met bloedgroep 0.

    Die bloedgroep kan aan mensen met alle andere bloedgroepen worden toegediend, wat in noodsituaties tijdwinst oplevert. Dat maakt het project bijzonder interessant voor het leger, voor de behandeling van gewonden in gevechtssituaties.

    Zuurstoftransport

    De wetenschappers willen stamcellen stimuleren om uit te groeien tot rode bloedlichaampjes, die het transport van zuurstof door het lichaam voor hun rekening nemen en daarmee een van de belangrijkste functies van bloed vervullen.

    Theoretisch kan met één embryo genoeg bloed worden geproduceerd voor heel Groot-Brittannië. Ook wordt het risico op besmetting door 'fout' bloed kleiner.

  18. [verwijderd] 23 maart 2009 21:23
    Drug Stocks Rise As US Details Plan For Banks' 'Toxic' Debt

    Last update: 3/23/2009 11:10:36 AM

    By Val Brickates Kennedy

    Drug stocks rose along with the broader market early Monday, with biotech shares setting the pace, as U.S. Treasury Secretary Timothy Geithner unveiled the government's plan to help rid the financial system of so-called toxic debts that have stifled lending.

    The Amex Pharmaceutical Index climbed 0.8% to 240.22, and the Amex Biotechnology Index jumped 1.8% to 635.29. The Dow Jones Industrial Average pushed through the 7,500 mark as U.S. stocks staged a solid advance.

    Among the sharpest gainers in U.S. large-cap issues were Allergan Inc. (AGN), Eli Lilly & Co. (LLY) and Pfizer Inc. (PFE), while Dr. Reddy's Laboratories (RDY) led foreign drugmakers. Shares of Eli Lilly traded up 2.4% at $33.34, as the company said its combination drug Symbyax has become the first drug approved by the U.S. Food and Drug Administration for the acute treatment of treatment-resistant depression, or TRD. Symbyax is a combination of the company's top-selling antipsychotic Zyprexa and the anti-depressant Prozac, which lost patent protection several years ago. Eli Lilly noted that the FDA also approved Zyprexa and Prozac to be used in combination to treat TRD and for the acute treatment of biopolar depression. Prozac is now available generically. Meanwhile, Amylin Pharmaceuticals (AMLN) shares rose 4% to $11.75, gaining amid speculation over whether the FDA will approve a rival product to its diabetes medication Byetta. Amylin co-markets Byetta with Eli Lilly. On April 2, an FDA advisory panel will decide whether to recommend liraglutide, the rival medication from Novo Nordisk A/S (NVO), for approval.

    Both products are used to control blood-sugar levels in diabetics. U.S.-listed shares of Novo Nordisk moved up 1% to $45.80. The same FDA advisory panel will be reviewing another diabetes drug, saxagliptin, on April 1. The product was developed by Bristol-Myers Squibb (BMY) and AstraZeneca PLC (AZN). Shares of Bristol-Myers were up 1% at $20.76, while AstraZeneca traded largely flat at $32.96. Also higher, shares of Forest Laboratories (FRX) advanced 2% to $21.48. On Friday, the FDA approved its popular antidepressant Lexapro for the treatment of major depression in teenagers, making it only the second medication to receive such a designation.

    -Val Brickates Kennedy; 415-439-6400; AskNewswires@dowjones.com
  19. [verwijderd] 23 maart 2009 21:35
    2 Potential Pharma M&A Targets: Cephalon and Genzyme
    March 23, 2009

    Bullish Bankers

    As M&A activity peppers the Healthcare industry, prudent investors are searching for the next big acquisitions. 2008 left I-banks hanging their heads as weak market conditions and restricted lending created a stale environment for M&A activity. However, the dire need for drug companies to protect their future sales brings out the big players in the industry looking to strengthen their pipelines and diversify products to ease investors’ fears over the $160 billion in revenues of drugs coming off patent protection by 2016. Investors looking for M&A may want to keep their eye on these two attractive companies.

    Cephalon, Inc. (CEPH)

    Cephalon, Inc is a bio-pharmaceutical company that focuses on developing and selling drugs pertaining to central nervous system disorders, oncology, pain, and addiction. CEPH’s most bankable drug, Provigil, accumulated about $1 billion in revenue in 2008. Provigil is approved for the treatment of narcolepsy, shift work sleep disorder, and excessive daytime sleepiness linked to sleep apnea. Although this drug is coming off its patent in 2015, the company has already acquired a patent on Provigil’s successor, Nuvigil, which expires in 2023. Nuvigil is the enantiomeric (mirror) version of Provigil and is expected to not only take over most of Provigil’s market share, but be approved for more uses as well. Nuvigil is expected to be released in the 3rd quarter of 2009.

    With a market cap of $4.58 billion and a young potential blockbuster drug (based on its predecessor), Cephalon’s leading position in the ”wakefulness market” makes it an attractive target that can complement the pipeline of many of the bigger name drug companies that will suffer from patent expiration.

    I wouldn’t be surprised to see GlaxoSmithKline (GSK) move for Cephalon. GSK has 3 drugs that bring in a little over 30% of its pharmaceutical revenue. Scarier still is the fact that its second most bankable drug, Lamictal, has been expired since July 2008 and will easily lose market share to Teva’s (TEVA) generic version. GSK boasts a long list of drugs in late stage clinical trials, but when it comes to sales, it may quickly run out of blockbuster drugs unless it acquires Cephalon. Its business segments mesh perfectly, with both heavily focusing on the central nervous system and oncology. Better still, none of its leading drugs overlap each other. For a great price, GlaxoSmithKline can grab greater exposure in markets it is already familiar with. Cephalon’s pipeline longevity will add stability to GSK during a time of uncertainty in the pharmaceutical industry that is certain to occur.

    Genzyme (GENZ)

    Genzyme is a biotechnology company that focuses on manufacturing and marketing expensive orphan drugs in niche markets. The main sources of Genzyme’s revenue come from 7 drugs covering the Therapeutics and Renal business segments. At #1 in 12 different drug markets, no other orphan drug company comes close to touching Genzyme in size or market share. They boast a diverse and robust pipeline with 16 drugs in late stage clinical trials and an additional 4 drugs with patents expiring in over 5 years. However, Genzyme’s star drug, Cerezyme, which pulled in $1.2 billion in 2008, has only 2 years left on its first patent. Although this is considered a setback, GENZ’s answer to Pompe Disease, Myozyme, is projected to become an even greater source of revenue for its Therapeutics business segment as it gains FDA approval for more uses.

    The patent expiration problem will have a far-reaching effect on the way big pharmaceuticals grow their core businesses, causing them to look to biotech for innovative products. This trend contributes to Genzyme’s already great potential of being acquired by a large pharmaceutical company. It wouldn’t be alarming if Bristol-Myers Squibb (BMY) announced a tender offer for the orphan drug company. By 2013, 3 drugs that bring in roughly 40% of BMY’s pharmaceutical revenue will come off patent protection. In order to keep up with other large pharmaceutical companies that have already made efforts to minimize the impact of expired patents, BMY will be pressured to partner up with a successful company with a proven record of scientific innovation. Genzyme offers this. Moreover, Genzyme will give Bristol-Myers access to its niche orphan drug markets, where it will enjoy the same tax breaks that Genzyme currently enjoys in the United States.

    Over the past 5 years, Genzyme has grown at a compounded rate of 22.98% and is on track to reach its projected annual growth rate of 20% through 2011. When the time comes for BMY’s star drugs to come off patent protection, Genzyme’s young drugs will have developed into a promising source of revenue. The unrivaled strength of Genzyme’s orphan drug pipeline and its ability to capitalize on untapped drug markets may end up preserving Bristol-Myers’ leading presence in the competitive pharmaceutical industry.

    -Brendan Steven

    seekingalpha.com/article/127323-2-pot...

  20. [verwijderd] 24 maart 2009 20:46
    Drug giants urged to create patent pools

    Sarah Boseley, health editor The Guardian, Tuesday 24 March 2009 Article history

    A government minister will today challenge drug companies to help the developing world by giving up their patent rights to compounds that could be used in cures for neglected diseases and medicines for children with HIV.

    Ivan Lewis, the minister for international development, said it was reasonable to expect the drug giants to do more. "Now is the time for industry to step up to the mark," he said.

    "We're all concerned about the economic circumstances we're living in and the danger that that will push an increasing number of people into poverty," he added. "Challenging pharma to do their bit ... is entirely legitimate."

    Lewis plans to meet executives of leading drug companies to ask them whether they will participate in two patent pool initiatives. He wants to know whether they will respond to the invitation of the British company GlaxoSmithKline, which a few weeks ago said it would put all relevant patents into a pool designed to facilitate research into drugs for neglected diseases, and invited other companies to do the same.

    GlaxoSmithKline's chief executive, Andrew Witty, told the Guardian at the time: "I can't tell you how many speeches I've heard about, you know, 'I wish we could make progress on TB' or 'Why haven't we got treatments for these things?' We all sit there saying well yes, it's terrible isn't it, instead of actually trying to do something about it. So ... what I really hope this does is stimulate people to start engaging with us, and maybe other people to say, look, actually, if you did it this way it could really work."

    Witty said he knew other chief executives worried about this too, adding: "Who knows, maybe somebody has to move before many people move." So far, however, there has been no similar declaration from other drug companies.

    Lewis will also be asking chief executives whether they will support a patent pool for HIV medicines being designed by Unitaid, an international organisation launched by France, Brazil, Chile, Norway and the UK that buys medicines for the developing world.

    "There's never been a better time for other companies to make their position known," he said.

    The minister also intends to press Unitaid to move faster. He will write to the agency "urging them to speed up their work specifically on the question of child-friendly HIV treatments".

    New medicines for TB are among those needed as the global epidemic grows, fuelled by HIV and complicated by resistance to old drugs. Today, which is World TB Day, Lewis will announce £18m research funding for the TB Alliance to develop a shorter course of treatment.

    The UK is making the grant against a background of concern that recession may cause donors to cut back on funding for poor countries.

    www.guardian.co.uk/society/2009/mar/2...
690 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 35 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 882,27 -0,04%
EUR/USD 1,0726 +0,29%
FTSE 100 8.147,03 +0,09%
Germany40^ 18.128,50 -0,18%
Gold spot 2.344,37 +0,27%
NY-Nasdaq Composite 15.927,90 +2,03%

Stijgers

Philip...
+29,35%
Alfen ...
+14,76%
EBUSCO...
+6,88%
FASTNED
+4,79%
EXOR NV
+3,96%

Dalers

Vastned
-6,87%
VIVORY...
-5,88%
ASMI
-4,39%
ADYEN NV
-2,42%
BESI
-2,42%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!